Small changes can make a big difference in your powers of persuasion
What one word can you start using today to increase your persuasiveness by more than fifty percent?
Which item of stationery can dramatically increase people's responses to your requests?
How can you win over your rivals by inconveniencing them?
Why does knowing that so many dentists are named Dennis improve your persuasive prowess?
Every day we face the challenge of persuading others to do what we want. But what makes people say yes to our requests? Persuasion is not only an art, it is also a science, and researchers who study it have uncovered a series of hidden rules for moving people in your direction. Based on more than sixty years of research into the psychology of persuasion, "Yes " reveals fifty simple but remarkably effective strategies that will make you much more persuasive at work and in your personal life, too.
Co-written by the world's most quoted expert on influence, Professor Robert Cialdini, "Yes " presents dozens of surprising discoveries from the science of persuasion in short, enjoyable, and insightful chapters that you can apply immediately to become a more effective persuader. Why did a sign pointing out the problem of vandalism in the Petrified Forest National Park actually "increase" the theft of pieces of petrified wood? Why did sales of jam multiply tenfold when consumers were offered many "fewer" flavors? Why did people prefer a Mercedes immediately after giving reasons why they prefer a BMW? What simple message on cards left in hotel rooms greatly increased the number of people who behaved in environmentally friendly ways?
Often counterintuitive, the findings presented in "Yes " will steer you away from common pitfalls while empowering you with little known but proven wisdom.
Whether you are in advertising, marketing, management, on sales, or just curious about how to be more influential in everyday life, "Yes " shows how making small, scientifically proven changes to your approach can have a dramatic effect on your persuasive powers.

The incidence and prevalence of type 2 diabetes mellitus have increased dramatically in modernized and developing nations over the past few decades. Thoroughly revised and expanded, this Second Edition responds to the epidemic and supplies a current overview and guide to the management of diabetes in the modern healthcare environment. This Second Edition offers a current perspective on diabetes demographics, epidemiology, pathophysiology, disease monitoring, and approaches to glucose control, and supplies new chapters by world-renowned experts on non-pharmacological management options, complications of the skin and urogenital function, related macrovascular conditions, coronary heart disease, stroke, and peripheral vascular disease, and rare forms of diabetes, PCOS, and NASH.

Water resource management in the United States is evolving in the face of continuing challenges to protect water quality, provide adequate quantities of water for competing uses, and protect habitat and other natural resources. In many jurisdictions and agencies this evolution is increasingly leading toward adoption of watershed management. This approach is characterized by planning and decision making on a watershed scale, integration of a variety of competing water resource priorities and goals, cooperation of multiple stakeholders and governmental agencies, and increased levels of public participation. While the number and diversity of watershed management initiatives underway in the United States is impressive, successful transition to this integrated approach remains challenging due to institutional, regulatory, and information barriers. In certain respects - Geographic Information Systems mapping, wetlands regulations, citizen participation - U.S. watershed initiatives are highly advanced and serve as models for efforts around the world. In other respects - cross jurisdictional coordination and cooperation, agreements on the sharing of resources, habitat protection and restoration - innovatie approaches implemented outside the U.S. show great promise and offer important lessons to U.S. decision makers. This report identifies the most promising watershed planning and management approaches from around the world; evaluates how they operate, their benefits and limitations; and assesses the degree to which these approaches could be successfully adapted to the U.S. context. Drawing on this international experience, the report is intended to inform policy makers and practitioners and to promote the implementation of integrated watershed management approaches that are most likely to succeed.

Though a US - China conflict is far from inevitable, major tensions are building in the Asia-Pacific region. These strains are the result of historical enmity, cultural divergence, and deep ideological estrangement, not to mention apprehensions fueled by geopolitical competition and the closely related "security dilemma." Despite worrying signs of intensifying rivalry between Washington and Beijing, few observers have provided concrete paradigms to lead this troubled relationship away from disaster. Meeting China Halfway: How to Defuse the Emerging US-China Rivalry is dramatically different from any other book about US-China relations. Lyle J. Goldstein's explicit focus in almost every chapter is on laying bare both US and Chinese perceptions of where their interests clash and proposing new paths to ease bilateral tensions through compromise. Each chapter contains a "cooperation spiral" - the opposite of an escalation spiral - to illustrate the policy proposals. Goldstein not only parses findings from the latest American scholarship but also breaks new ground by analyzing hundreds of Chinese-language sources, including military publications, never before evaluated by Western experts. Goldstein makes one hundred policy proposals over the course of this book, not because these are the only solutions to arresting the alarming course toward conflict, but rather to inaugurate a genuine debate regarding cooperative policy solutions to the most vexing problems in US-China relations.

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy.

The incidence and prevalence of type 2 diabetes mellitus have increased dramatically in modernized and developing nations over the past few decades. Thoroughly revised and expanded, this Second Edition responds to the epidemic and supplies a current overview and guide to the management of diabetes in the modern healthcare environment. This Second Edition offers a current perspective on diabetes demographics, epidemiology, pathophysiology, disease monitoring, and approaches to glucose control, and supplies new chapters by world-renowned experts on non-pharmacological management options, complications of the skin and urogenital function, related macrovascular conditions, coronary heart disease, stroke, and peripheral vascular disease, and rare forms of diabetes, PCOS, and NASH.

Using leadership to generate greater innovation, connectivity, and organizational transformation is crucial for success in this challenging era. The authors present here a new approach to leadership based on findings from complexity science. Integrating real case studies with rigorous research results, they explore the biggest challenges being faced in fast-paced organizations, and provide a host of concrete tools for leading during critical periods, catalyzing novelty, expanding networks, and generating transformative change throughout an organization.

In 1962, Thomas Kuhne coined the term "paradigm shift" while arguing that human knowledge advances by quantum leaps with interspersed smaller steps. Preparation for the major advance is generally not a concerted effort by thought leaders. Rather, a few (or one) visionaries gain insights into a process and are able to definitely demonstrate the accuracy of their worldview. Often, the epiphany does not occur during the intellectual lifetime of the discoverers. Medicine has had numerous such "paradigm shifts" including the compelling reworking of Galen's concepts of the body. Of note, the scientific world of the time explained the new views by arguing that the human body must have changed between the time of ancient Greece and modern Europe. The inauguration of cardiac surgery itself required profound shifts in medicine's view of physiology. Yet, over the ensuing 40 years, the field was fine tuned so we could provide greater than 95% success rates in elective surgery with low cost and short h- pital stays. In some parts of the world, the procedures were viewed as commodities and prices dropped as providers were unable to differentiate the quality of their work. As patients and their physicians became more demanding, the desire to make the procedures "minimally invasive" grew. In effect, what we were really searching for was a life saving procedure that also preserved quality of life. In short, "minimally invasive" has really been a code phrase for procedures that disrupt our quality of life the least.

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy.